320 related articles for article (PubMed ID: 33300850)
1. Expanding spectrum of opportunistic infections associated with dimethyl fumarate.
Kim T; Croteau D; Brinker A; Jones DE; Lee PR; Kortepeter CM
Mult Scler; 2021 Jul; 27(8):1301-1305. PubMed ID: 33300850
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
Jordan AL; Yang J; Fisher CJ; Racke MK; Mao-Draayer Y
Mult Scler; 2022 Jan; 28(1):7-15. PubMed ID: 32808554
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion.
Garcia J; Hendel-Chavez H; De-Goer MG; L'Honneur AS; Dubessy AL; Taoufik Y; Stankoff B
Mult Scler; 2021 Apr; 27(4):640-644. PubMed ID: 32686582
[TBL] [Abstract][Full Text] [Related]
4. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.
Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J
Mult Scler; 2019 Oct; 25(12):1682-1685. PubMed ID: 31208265
[TBL] [Abstract][Full Text] [Related]
5. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
[TBL] [Abstract][Full Text] [Related]
6. PML in a patient with lymphocytopenia treated with dimethyl fumarate.
Rosenkranz T; Novas M; Terborg C
N Engl J Med; 2015 Apr; 372(15):1476-8. PubMed ID: 25853765
[No Abstract] [Full Text] [Related]
7. Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies.
Khatri BO; Tarima SS; Essig B; Sesing J; Olapo T
Mult Scler Relat Disord; 2017 Nov; 18():60-64. PubMed ID: 29141823
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with dimethyl fumarate-induced lymphopenia.
Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
[TBL] [Abstract][Full Text] [Related]
9. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
[TBL] [Abstract][Full Text] [Related]
10. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate.
Nieuwkamp DJ; Murk JL; van Oosten BW; Cremers CH; Killestein J; Viveen MC; Van Hecke W; Frijlink DW; Wattjes MP;
N Engl J Med; 2015 Apr; 372(15):1474-6. PubMed ID: 25853764
[No Abstract] [Full Text] [Related]
11. Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
Van Schependom J; Gielen J; Laton J; Nagels G
Mult Scler; 2016 Mar; 22(3):389-92. PubMed ID: 26199353
[TBL] [Abstract][Full Text] [Related]
12. Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate.
Lyons J; Hughes R; McCarthy K; Everage N; Kapadia S; Miller C; Singhal P; Smirnakis K
Mult Scler J Exp Transl Clin; 2022; 8(4):20552173221132469. PubMed ID: 36387034
[TBL] [Abstract][Full Text] [Related]
13. Diffuse dermatophytosis occurring on dimethyl fumarate therapy.
Greenstein JI
Mult Scler; 2018 Jun; 24(7):999-1001. PubMed ID: 29649923
[TBL] [Abstract][Full Text] [Related]
14. Effects of dimethyl fumarate on lymphocyte subsets.
Berkovich R; Weiner LP
Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
[TBL] [Abstract][Full Text] [Related]
15. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
Calabrese M; Pitteri M; Farina G; Bajrami A; Castellaro M; Magliozzi R; Monaco S
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1073-1078. PubMed ID: 28844068
[TBL] [Abstract][Full Text] [Related]
16. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.
Balak DMW; Hajdarbegovic E; Bramer WM; Neumann HAM; Thio HB
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1475-1482. PubMed ID: 28322482
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature.
Dello Russo C; Scott KA; Pirmohamed M
Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427
[TBL] [Abstract][Full Text] [Related]
19. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M
J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861
[TBL] [Abstract][Full Text] [Related]
20. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
